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or caspofungin acetate (CAS). Endpoints were sur- 
vival, colony forming units (CFUs), and histology of 
lungs. 
Results: Initially, we compared the efficacy of a 
single dose of LAmB at 15 mg/kg to a dual treat- 
ment close of 7.5mg/kg given every other day. 
The single 15mg/kg close and the second of the 
dual 7.5 mg/kg doses were administered 24, 48 or 
72 hours prior to infection. Only administration of 
dual 7.5 mg/kg doses of LAmB at 24 or 48 h prior to 
infection resulted in equivalent, significant protec- 
tion as compared to placebo (100% vs 50%, p <0.05). 
This data indicated that the total amount of LAmB 
administered over time was more important han 
the individual amount of each dose. Next, we com- 
pared dual doses of LAmB at 7.5 mg/kg with ABLC 
at 7.5 mg/kg, AmB at 1 mg/kg, and CAS at 1 mg/kg 
given on days -4 and -2 prior to infection. Addi- 
tionally, CAS was also administered as a single dose 
6 hours prior to infection. Only LAmB and the single 
dose arm of CAS significantly improved survival 
compared to placebo (75% and 88% vs 25% survival 
of placebo, p < 0.04). Lung CFUs was significantly 
reduced by prophylactic administration of LAmB 
(p=0.005), AmB (p=0.03), or CAS (given 6 h prior 
to infection, p=0.0002) but not ABLC. These re- 
suits were mirrored in histopatho[ogica[ evaluation 
since lungs from mice receiving placebo and ABLC 
revealed large amounts of elongated hyphae with 
moderate necrotizing pneumonia, whereas lungs of 
mice treated with LAMB, AmB, or CAS did not. 
Conclusions: These data indicate that LAmB ad- 
ministered aily or every other day is a promising 
candidate for prophylaxis against pulmonary as- 
pergillosis in neutropenic hosts. CAS also mediates 
prophylactic effect, but must be dosed more often 
than LAmB for efficacy. 
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Immunotherapy in the Treatment of Systemic 
Adenovirus Infections 
L. Lenaerts*, E. De C[ercq, E. Verbeken, 
L. Naesens. Rega Institute [or Medical Research, 
Katholieke Universiteit Leuven, B-3000 Leuven, 
Belgium 
Background: Severe adenovirus infections are of 
increasing concern in AIDS patients and trans- 
plant recipients under immunosuppressive th rapy. 
Unfortunately, current therapeutic moda[ities for 
adenovirus infections are limited. 
Objectives: We investigated the contribution of 
the host's adaptive immune response and the ef- 
ficacy of immunotherapy in the control of systemic 
adenovirus infections using two mouse models. 
Methods ~ Results: Severe combined immune 
deficient (SClD) mice, intranasa[[y inoculated with 
mouse adenovirus type 1 (MAV-1), develop a fa- 
tal disseminated isease characterized by hem- 
orrhagic enteritis (Lenaerts et aL, 2005, Antimi- 
crob Agents Chemother 49, 4689-99). When SCID 
mice were treated with antisera containing MAV-1 
specific IgG, MAV-l-induced death was significantly 
delayed from day 18 p.i. (untreated mice) to day 
42-60 p.i. (antiserum-treated mice). The extent of 
the delay was dependent on the titer of MAV-1 neu- 
tralizing antibodies in the antiserum. The MAV-1 
antisera were obtained from immunocompetent 
mice challenged with MAV-1 and were transferred 
to the MAV-l-infected SCID mice at day -1 and 
day 9 post infection. Ultimately, MAV-l-infected 
SCID mice treated with the MAV-l-antisera showed 
100% mortality, with identical pathology and simi- 
lar virus titers in the target organs as seen in un- 
treated, infected SCID mice. These results indicate 
that antibodies play a major role in protection and 
elimination of systemic adenovirus infection. In an 
alternative mouse mode[ for adenovirus infection, 
cyc[ophosphamide (CY) was administered to adult 
BALB/c mice to induce a genera[ and reversible 
immunosuppression. MAV-l-re[ated mortality cor- 
related with the duration of immunosuppressive 
therapy. Mice receiving CY for 3 or more weeks 
succumbed to an identical pathology and similar 
virus titers in the affected tissues as seen with 
MAV-l-infected SCID mice. On the contrary, mice 
in which immunosuppressive therapy was ceased 
1 week post infection did not develop symptoms 
and survived. These mice showed high serum titers 
(~>1:160) of MAV-1 neutralizing antibodies. Studies 
are ongoing to evaluate the efficacy of antivira[s 
(such as cidofovir) in this MAV-1/CY mode[. 
Conclusions: These two new mouse models wi[[ in- 
crease our understanding of the suppression of ade- 
novirus disease by antivira[ and/or immunotherapy 
and wi[[ be helpful in the development of an ade- 
quate treatment for systemic adenovirus infections 
in immunocompromised patients. 
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Background: Advisability of vaccination against the 
HBV infection in patients with 'isolated' HBcAb 
Infections in Other Immunocompromised Hosts $43 
remains debatable. As many as 300 (or 33.4%) out 
of 897 haemodialysis (HD) patients of our center 
were positive for HBV-antibodies. 'Isolated' anti- 
HBc (HBsAg, HBsAb were not found) were detected 
in 194 patients (64.7%), while HBsAb was found only 
in 31 patients (10.3%), and HBsAb together with 
HBcAb were found in 75 patients (25%). 
Methods: Twenty seven HD patients (age 44.3±2.6; 
15 males, 12 females)with 'isolated' HBcAb were 
randomly assigned for study a new approaches of 
immunization against HBV infection. Schedule of 
vaccination of A.Mclntyre et al. (1992) was adapted 
for HD patients. All patients were immunized by 
40 mcg of HBV vaccine 'Combiotech' (Russia). Blood 
samples were obtained for quantitative determina- 
tion of HBsAb in 1 month after the first vaccination. 
If the HBsAb titers were higher than 50mlU/ml, 
the immunization was terminated. In this case 
'isolated' HBcAb could be considered as a sign of 
past HBV infection. In patients with lower level of 
HBsAb vaccination was continued using a 'standard' 
schedule for HD patients (1-2-6 months). 
Results: The HBsAb titers a month after the end of 
immunization are shown in Table 1. 
Tab[e 1. Resu[ts of vaccination of patients with 'iso[ated' HBcAb 
and with HBsAb <50mlU/m[ one month after the first vaccine 
injection. 
HBsAb HBsAb (mlU/m[) at end of vaccination 
(mlU/m[) 1 mo after first injection 
< 10 10-99 100-499 < 500 Tota[ 
<10 1 3 2 - 6 
10-50 - 3 3 2 8 
Total 1 6 5 2 14 
Conclusion: Nearly half of the patients with the 
'isolated' HBcAb responded by a protective titer 
only after complete course of immunization. Pos- 
sibly the detection of this marker had pseudo- 
positive character. Thus, the suggested vaccination 
scheme allows one to increase its efficiency in HD 
patients with 'isolated' HBcAb. 
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Background E Methods: Vaccination efficacy 
against the HBV infection was studied in 175 
haemodialysis (HD) patients (96 males, 79 fe- 
males, 49±0.8 years old) who had no signs of 
HBV infection (no HBsAg, HBsAb and HBcAb). The 
duration of the HD therapy prior to immuniza- 
tion was 10.2±0.7 months. Chronic renal failure 
mainly resulted from chronic glomerulonephdtis in 
33.1% of patients, diabetic nephropathy (19.4%) 
and chronic pyelonephdtis (16.6%). Patients were 
immunized with "Engerix B" (GlaxoSmithKline) or 
"Combiotech" (Russia) by injecting 40 mcg of vac- 
cine at 0th, 1st, 2nd and 6th month. 
Results: The results were monitored for 36 months 
after the end of vaccination. In one month the 
HBsAb titers of 10 mlU/ml or higher were found in 
147 patients (84%). The dynamics of the level of the 
HBsAb titers during the next 36 months is shown in 
Table 1. The number of patients with the HBsAb 
titres less than 10mlU/ml divided by the number 
of patients having certain HBsAb level at the end 
of immunization is presented. 
Tabte 1. Number of patients with HBsAb < 10 mlU/m[ at different 
stages of fottow-up at different revers of post-immunization 
titres 
HBsAb 18mo 24mo 30mo 36mo 
(mlUlm[) (n =97) (n =78) (n = =69) (n =40) 
n % n % n % n % 
10-99 10/18 56 13/15 87 13/15 87 13/13 100 
100-499 4/25 16 5/16 31 6/13 46 8/9 89 
500 0/54 0 1/47 2 3/41 7 7/18 39 
Conclusion: The rate of decreasing of protective 
antibody titers in HD patients depended on re- 
sponse intensity at the end of vaccination. It may 
be the rationale for revaccination in HD patients. 
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Background: EBV related PTLD has been recog- 
nized as a serious complication of immunosuppres- 
sion in patients undergoing bone marrow trans- 
plants, and solid organ transplants. The presence of 
EBV related PTLD outside of the transplant world, 
has been reported less frequently. We report a 
case of biopsy confirmed polyclonal EBV PTLD in a 
patient with Crohns disease, and successful treat- 
ment with gancidovir. 
Case: A 17 yr female with a known history of 
Crohns disease presented in August with symptoms 
